Immuneering Conference Call Summary Company Overview - **Company**: Immuneering - **Focus**: Development of atebumetanib for treating first-line pancreatic cancer Key Industry Insights - **Industry**: Oncology, specifically pancreatic cancer treatment - **Current Treatment Landscape**: Standard of care includes gemcitabine plus nab-paclitaxel (GNP), with overall survival rates significantly lower than those reported for atebumetanib Core Points and Arguments 1. **Overall Survival Data**: - 12-month overall survival rate for patients treated with atebumetanib plus chemotherapy is 64% [7][21] - Historical benchmark for standard of care (GNP) is approximately 35%, indicating a 29-point absolute separation [8][21] - Median overall survival for standard of care is about 8.5 months, while median for atebumetanib has not yet been reached [8][11] 2. **Quality of Life Improvements**: - Significant improvements in quality of life reported, with specific case studies highlighting patients regaining independence and experiencing less severe side effects [5][18] - Functional Assessment of Anorexia Cachexia Therapy (FAACT) score improved from 96 to 141 in a patient case study [18] 3. **Safety and Tolerability**: - Favorable safety profile with few severe side effects; only anemia and neutropenia occurred in over 10% of patients [10] - No harsh side effects observed with atebumetanib monotherapy, differentiating it from traditional chemotherapy [10] 4. **Clinical Trial Plans**: - Upcoming pivotal phase 3 trial (MapKeeper 301) will enroll approximately 510 patients, comparing atebumetanib plus modified gemcitabine nab-paclitaxel against standard GNP [20] - Primary endpoint will be overall survival, with dosing expected to begin mid-year [20] 5. **Expanded Cohort Data**: - An expanded cohort of over 50 patients is being reported, with overall survival trending consistently with the original cohort of 34 patients [12][49] - The expanded cohort includes additional patients who started treatment later, but results remain robust [49] 6. **Market Positioning**: - Immuneering aims to position atebumetanib as a best-in-class treatment for pancreatic cancer, with the potential to become the new standard of care [52] - The company emphasizes the importance of both quality and quantity of life for patients, aiming to provide effective treatment without debilitating side effects [34][52] Additional Important Content - **Patient Demographics**: The trial population is older, with a median age of 69, which reinforces the significance of the survival benefits observed [12] - **Future Milestones**: Upcoming milestones include sharing circulating tumor DNA analyses and updated survival data, as well as the initiation of phase 2 combination studies in lung cancer [21][22] This summary encapsulates the key points discussed during the Immuneering conference call, highlighting the promising data surrounding atebumetanib and its potential impact on the treatment of pancreatic cancer.

PresentationGood afternoon, ladies and gentlemen, and welcome to the continued improvement in PFS with iSCIB1+ in advanced melanoma Phase II update, ESMO IO. [Operator Instructions] I would like to remind all participants that this call is being recorded.Phillip L'HuillierCEO & Director Thank you. Good afternoon. Good morning, everyone. Thank you for joining us today. Today, I'm excited to share with you an update on the SCOPE data. And we're calling this presentation redefining the standard of care of adva ...

Core Insights - Genentech, a member of the Roche Group, announced positive results from the Phase III evERA Breast Cancer study [1] - The study demonstrated that giredestrant in combination with everolimus significantly reduced the risk of disease progression or death [1] Study Results - The combination therapy reduced progression-free survival (PFS) by 44% in the intention-to-treat (ITT) population [1] - In the ESR1-mutated population, the risk of disease progression or death was reduced by 62% compared to standard-of-care endocrine therapy plus everolimus [1]